News

Alvotech has launched a Phase 1 clinical trial to test the safety and efficacy of AVT05, its biosimilar drug candidate to Simponi (golimumab) — being developed for the treatment of ankylosing spondylitis (AS) and other diseases marked by inflammation. The study (NCT05632211) is enrolling more than…

Health Canada has approved a high-concentration formulation of Hadlima (adalimumab-bwwd), a biosimilar to Humira (adalimumab), for treating ankylosing spondylitis (AS) and other diseases. A biosimilar is a medical product designed to be identical — with similar properties, as well as comparable safety and effectiveness — to an…

Some immune T-cells that react to microbial proteins also target normal human proteins in people who carry HLA-B27 variants, the strongest genetic risk factor contributing to ankylosing spondylitis (AS), a study revealed. The shape of the protein fragments targeted by the immune T-cells, whether human or bacterial, was almost…

The biotech company Girihlet will collaborate with Mayo Clinic to develop an algorithm that evaluates the effects of immune-suppressing treatments in patients with ankylosing spondylitis (AS), Girihlet announced. Under the so-called “know-how agreement,” Girihlet will use its proprietary ImmuneScanner technology to monitor changes in immune T-cells…

Pregnant women with axial spondyloarthritis (AxS) are not at an increased risk of preeclampsia, unlike those with other rheumatic conditions, a new study suggests. Using more than 3,000 health records, researchers in Sweden and Denmark evaluated preeclampsia risk in pregnant women with rheumatoid arthritis (RA), AxS, and psoriatic arthritis. “Based…

Platelet counts and blood levels of inflammatory proteins interleukin-23 (IL-23) and interleukin-17 (IL-17) were identified as the strongest potential non-genetic biomarkers of ankylosing spondylitis (AS) in a recent umbrella review study. The study, which looked at 43 previously identified biomarkers, found the evidence was weak for most others. The…

Six weeks of water-based exercises — consisting of stretching or Pilates — led to significant reductions in pain and improvements in spine flexibility, functional capacity, and quality of life for men with ankylosing spondylitis (AS), according to a recent study in Iran. While both types of exercise led to…

AVT02, a high-concentration and low-volume biosimilar to AbbVie’s Humira (adalimumab), was approved by health regulators in Australia to treat inflammatory disorders such as ankylosing spondylitis (AS). A biosimilar is a biological medicine with a high degree of similarity — in terms of quality, safety, and efficacy —…

One year of UCB Biopharm‘s investigational therapy bimekizumab, administered subcutaneously (under the skin) once every four weeks, resulted in sustained improvement in the signs and symptoms of axial spondyloarthritis (axSpA), according to late-breaking data from two BE MOBILE Phase 3 clinical trials. axSpA is a type of inflammatory…

Early initiation of anti-tumor necrosis factor (TNF) medications may be associated with an increased risk of cardiovascular events in people with ankylosing spondylitis (AS), a study suggests. “We designed the study with the overall hypothesis that the use of TNF inhibitors, which reduce inflammation and thus cardiovascular risk,…